What’s more, vehicle manufacturers warn that regularly using a public EV fast charger can actually shorten battery life. With recent large-scale transformations to the power and energy industry ...

The Los Angeles Chargers didn’t make a move at the NFL trade deadline, to the disappointment of at least a portion of the fanbase. But they did start to make roster moves after the deadline.

Joe Hortiz made aggressive moves this offseason, but when it came to Tuesday’s NFL trade deadline, the Chargers’ general manager stood firm with the roster he built. The Chargers didn’t ...

According to Boston Sports Journal’s Mike Giardi, the Chargers are one of the teams that has shown interest in trading for Patriots wide receiver K.J. Osborn. Osborn hasn’t been that productive this ...

SAN AN­TO­NIO — Promis­ing da­ta don’t al­ways equal a stock pop. Viking Ther­a­peu­tics pre­sent­ed what an­a­lysts thought were com­pelling da­ta on an oral … ...

The Chargers are relevant -- and well-coached. Times may be tough in places such as Dallas, Jacksonville, Las Vegas, New Orleans and, suddenly, Chicago. But the intrigue level remains high in a ...

The Los Angeles Chargers are just getting rolling. After back-to-back wins over the New Orleans Saints and Cleveland Browns, the team sits at 5-3 and is well within striking distance of a playoff ...

CLEVELAND, Ohio — Jameis Winston cleared up a big mystery during Sunday’s 27-10 Browns loss to the Chargers. Everyone wondered after the his 334-yard, 3 TD game against the Ravens last week if ...

The Week 11 game between the Cincinnati Bengals and Los Angeles Chargers will now be on "Sunday Night Football," CBS Sports lead NFL insider Jonathan Jones confirms. The game was originally Nov.

Nov 4 (Reuters) - Viking Therapeutics (VKTX.O), opens new tab shares reversed course to fall 8% on Monday as focus shifted to the drug developer's ability to mass produce its oral obesity ...

Getty Images Viking Therapeutics shares fell Monday after reporting the latest results from trials of its weight-loss drugs. Analysts say the treatment, which is being tested in both oral and ...

Viking Therapeutics is rowing its longboat toward the front of the oral obesity therapy race, posting detailed phase 1 data that suggest its dual agonist of GLP-1 and GIP can hold its own in a ...